A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

  • STATUS
    Not Recruiting
  • participants needed
    38
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 14 September 2023
myeloid leukemia
myelodysplastic syndromes
cytarabine
chronic myelomonocytic leukemia
direct bilirubin
growth factor
leukemia
induction chemotherapy
refractory acute myeloid leukemia (aml)
venetoclax
lenalidomide
IDH2
myelomonocytic leukemia

Summary

The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).

Details
Condition Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Treatment E7820
Clinical Study IdentifierNCT05024994
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on14 September 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note